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Case Description
A 41-year-old female from Mexico living in the United States
over the past 7 years presented with a 4-month history of slowly
progressive painless subcutaneous swelling and deformity on the
anteromedial aspect of her right foot with multiple sinus tracts with
intermittent serosanguineous drainage mixed with yellow grains
(Figure 1). She reported the occurrence of a similar episode in the
same affected area 13 years prior. At that point, she was treated
with an unknown combination of two oral antibiotics for a 3-year
period that resulted in significant clinical improvement.
Prior to coming to the US, she lived in an impoverished rural
area of Guanajuato, Mexico. Since early childhood, she had
participated in farming activities, and was often barefoot due to a
lack of shoes. She denied any associated systemic symptoms such
as fever, weight loss, or malaise. As the swelling progressively
increased, she developed difficulty walking.
Diagnosis
Actinomycetoma caused by Nocardia brasiliensis.
Mycetomas are chronic subcutaneous inflammatory granulo-
matous infectious processes that are divided into two types:
eumycetoma or true mycetoma caused by fungi, and
actinomycetoma caused by aerobic filamentous bacteria [1–6].
Actinomycetomas are caused by members of the genera Nocardia,
Streptomyces, Nocardiopsis, and Actinomadura. Fungal mycetomas are
most frequently caused by members of the genera Madurella and
Acemonium [3]. Of these, Madurella mycetomatis is the most prevalent
causative mycetoma-inducing agent [4,5]. The term mycetoma,
coined by Vandyke Carter in 1860, suggests a fungal tumor [1,7];
however, aerobic filamentous bacteria cause most cases worldwide
(60% of cases) [3,5]. Mycetomas are also frequently identified as
‘‘Madura foot’’. It is presumed that the first description of this
entity occurred in 1842 in the Madras Medical Service of the
British Army in India, and hence the term Madura foot [1,7,8].
Mycetomas occur among the poorest people living in resource-
limited settings and produce considerable disability, disfigurement,
and stigma. Mycetomas are therefore listed as neglected tropical
diseases on the PLoS Neglected Tropical Diseases Web site (http://
www.plosntds.org /static/scope.action) [9]. There is a wide
geographical distribution of the various microorganisms that cause
mycetomas depending on climate, rainfall, and ecologic factors
[2,3]. In general, mycetomas are endemic in relatively arid zones
with short rainy seasons and low relative humidity [3]. A
mycetoma belt has been described between the latitudes of 15uS
and 30uN [1]. Mycetomas are usually endemic in some tropical
and subtropical areas [2–5]. Most reported cases are from Mexico,
Venezuela, Brazil, and Colombia in the Americas; India and
Pakistan in the Indian subcontinent; and Somalia, Sudan, and
Senegal in Africa [3–5]. Regardless of the causative microorgan-
ism, mycetomas tend to affect people who live in rural areas
and are involved in outdoor activities [2], and onset of the
microorganism establishment might result from traumatic inocu-
lation of infectious fungi or bacteria present in the soil [3].
It has been suggested that eumycetomas usually predominate in
Southeast Asia and Africa and actinomycetomas in the Americas.
However, there is some data to suggest an increasing number of
eumycetomas in South America [3]. N. brasiliensis is the most
common cause of actinomycetomas, particularly in the Americas
[3,4]. In Mexico, mycetomas are often identified among
impoverished farm workers in rural arid settings in the mainland
states of Guanajuato, Oaxaca, and Morelos [2]. In these settings,
actinomycetomas are responsible for 90% of mycetomas. N.
brasiliensis causes 85% of cases, followed by Actinomadura madurae in
8% and Streptomyces somaliensis in 3% of cases. Eumycetomas are
rarely reported in Mexico. The most frequent fungi have included
Madurella grisea, M. mycetomatis, and Acremonium [2].
Clinical suspicion of mycetomas is based on the clinical triad
that includes the presence of slowly progressive painless subcuta-
neous swelling, sinus tract formation, and granular discharge [1–5]
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of the body including the hand, head, neck, and back [2–4].
Actinomycetomas tend to progress more rapidly than eumyceto-
mas, producing more inflammatory and destructive lesions [3]. In
these sites, infection is usually localized, but involvement of deeper
structures such as bone, tendons, and muscles may sometimes be
identified [1,4]. Dissemination to other organs such as the lung
and vertebrae has been rarely reported [2,3].
Diagnosis of mycetoma relies on direct examination of grains
and isolation of the etiologic agents. The discharging grains
represent aggregates of bacterial filaments or fungal hyphae [3].
The salient features of the grains may assist in the clinical
diagnosis: eumycetomas due to Madurella spp. typically produce
black grains [2]; actinomycetomas never produce dark grains, and
usually are yellow to orange; and those caused by Actinomadurae
pelletieri are red to pink [2,4,5]. Analysis of mycetoma sampled for
further histological processing provides some clues to the potential
microorganism, but culture is the gold standard for diagnosis [2,3].
For fungi, molecular testing with PCR analysis has been developed
since culture of some fungi may be challenging [3,4]. Serologic
testing has been shown to be useful in some settings, but in general
it has demonstrated low sensitivity and specificity [1,10]. Imaging
studies are useful for defining the extent of disease; for example,
ultrasound can be used to demonstratecharacteristic hyperreflec-
tive echoes and thick-walled cavities [1]. When available,
computed tomography or magnetic resonance imaging or
magnetic resonance imaging has been used to define the extent
of disease.
Treatment of mycetoma is often challenging and depends
mainly on the causative agent (bacterial or fungal) and severity of
disease [1–3]. Actinomycetoma is amenable to medical therapy
with prolonged courses of antimicrobials even in advanced cases
[4,5]. Combined drug therapy is always preferred to avoid drug
resistance and to achieve microbiologic cure. The most common
antimicrobials used are sulfas (cotrimoxazole and dapsone),
aminoglycosides (streptomycin, amikacin), rifamycins (rifampin),
tetracyclines (minocycline), beta-lactams (amoxicillin/clavulanate),
or quinolones (ciprofloxacin) [3,4]. Treatment of mycetoma
caused by N. brasiliensis is less cumbersome than that caused by
other bacteria [3]. A combination of dapsone and cotrimoxazole
for 6 to 9 months is frequently used in resource-limited settings
with good results. This combination is associated with substantial
clinical improvement frequently observed within the initial 3
months of initiation of treatment [3]. More recently, the use of
carbapenems (imipenem and meropenem) and oxazolidinones
(linezolid) have shown to be effective in the therapeutic
armamentarium against actinomycetomas, but their use remains
limited in many settings due to cost and availability [2,3,6].
In contrast, for fungal mycetomas, a combination of medical
and aggressive surgical approaches has been traditionally recom-
mended [1–5]. Surgical debridement (sometimes requiring
amputation) together with medical therapy (prolonged courses of
triazoles) both prior to and after surgery is often the preferred
therapeutic strategy [1,5]. Recent data suggest that newer triazoles
(voriconazole or posaconazole) may decrease the need of
aggressive surgical interventions due to their higher efficacy, tissue
penetration, and better bioavailability [2,3]. However, their use
needs tobe long-term, and thus, their broader use in resource-
limited settings may be hampered by their cost [2].
In our patient, culture of one of the grains disclosed the
presence of N. brasiliensis. Her current episode may represent a
relapse of N. brasiliensis that was persisting from her initial episode,
of 13 years ago [2,4]. She has received a combination regimen of
daily oral trimethoprim/sulfamethoxazole and oral dapsone for
the past 3 months, with a reduction in foot swelling, and a
decreasing number of sinus tracts and drainage.Our plan is to
continue this antimicrobial combination for a prolonged period of
time (6 to 12 months), depending on her clinical response to this
regimen with laboratory monitoring (hemoglobin, methemoglobin
levels, and basic metabolic profile) for any potential side effects.
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Key Learning Points
N Mycetomas are divided into two types: eumycetomas
caused by fungi and actinomycetomas caused by
aerobic filamentous bacteria.
N Actinomycetomas generally respond more favorably to
antimicrobial therapy compared to eumycetomas, which
usually require surgical excision in addition to prolonged
antifungal therapy.
N Combined drug therapy is always preferred for actino-
mycetomas with a combination of sulfa drugs (dapsone,
bactrim) with either aminoglycosides (streptomycin,
amikacin) and/or rifamycins (rifampin). Other alternative
antimicrobials include tetracyclines, beta-lactams, or
quinolones.
N Carbapenems and oxazolidinones have emerged as
promising therapeutic strategies for actinomycetomas,
and newer triazoles for the treatment of eumycetomas.
However, their use in developing countries is currently
limited by their availability and cost.
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